A phase I randomized, double-blind, placebo-controlled, multi-dose study of PBI 4050 in patients with diabetic nephropathies
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2015
Price : $35 *
At a glance
- Drugs Setogepram (Primary)
- Indications Diabetic nephropathies
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors ProMetic Life Sciences
- 15 Nov 2015 Results from this phase Ib study have been presented at the American Society of Nephrology (ASN) annual meeting.
- 19 Mar 2015 Status changed from active, no longer recruiting to completed according to a ProMetic Life Sciences media release.
- 17 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to a ProMetic Life Sciences media release.